Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Satralizumab1件: Satralizumab (Satralizumab)1件: Satralizumab (Satralizumab, Satralizumab, satralizumab-mwge) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬4件: 11, 13, 86, 113 💬
2Satralizumab 120 MG1件: Satralizumab (Satralizumab)1件: Satralizumab (Satralizumab, Satralizumab, satralizumab-mwge) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
3Satralizumab prefilled syringe1件: Satralizumab (Satralizumab)1件: Satralizumab (Satralizumab, Satralizumab, satralizumab-mwge) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 113 💬